Ivonescimab plus chemotherapy for pretreated mesothelioma
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial is testing a new immunotherapy drug (ivonescimab) combined with chemotherapy for people with mesothelioma that has already been treated. It aims to see if this combination can shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are of Asian ethnicity and between 18 and 75 years old.
- You have been diagnosed with malignant pleural mesothelioma (a type of cancer in the lining of the lung).
- Your cancer has gotten worse after 1 or 2 prior treatments (like chemotherapy, immunotherapy, or anti-angiogenic therapy).
- You have at least one tumor that can be measured on scans.
- Your blood counts and kidney function are adequate (hemoglobin ≥90, neutrophils ≥1.5, creatinine clearance ≥50).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called ivonescimab for people with pleural mesothelioma (a cancer of the lung lining) that has grown back after earlier immunotherapy and chemotherapy. The drug may help by blocking a protein that tumors use to hide from the immune system, possibly slowing or shrinking the cancer.
This trial tests a new combination of two immunotherapy drugs plus standard chemotherapy and a targeted therapy for people with advanced mesothelioma who have not had treatment before. The goal is to see if this combination can shrink tumors and help people live longer.
This trial studies how well pembrolizumab (an immune therapy) works when added to chemotherapy before image-guided surgery for malignant pleural mesothelioma. It aims to shrink or control the cancer and improve surgical results by combining treatments.
This trial tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemotherapy helps people with malignant mesothelioma live longer and feel better. It's for patients who can't have surgery or radiation, and it may be an option if you haven't had treatment before or have had limited prior treatment.
This study tests a new immunotherapy drug (cadonilimab) when combined with chemotherapy for people whose pleural mesothelioma has come back or not responded to earlier treatment. The goal is to see if adding this drug can help shrink tumors or slow the cancer better than chemo alone.
This trial tests adding immunotherapy before surgery to help patients with sarcomatoid pleural mesothelioma. The goal is to shrink or control the cancer and make surgery possible, while checking safety.
Hear when a new Pretreated Pleural Mesothelioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.